Drug Profile
Indoximod - NewLink Genetics Corporation
Alternative Names: 1 MT; 1-methyl-D-tryptophan; 1-methyltryptophan; d-1-methyltryptophan; D-1MT; NLG-8189; NSC-721782Latest Information Update: 04 Jan 2019
Price :
$50
*
At a glance
- Originator Lankenau Institute for Medical Research
- Developer National Cancer Institute (USA); NewLink Genetics Corporation; University of Minnesota
- Class Amino acids; Antineoplastics; Indoles; Small molecules
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
-
Orphan Drug Status
Yes - Malignant melanoma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Malignant melanoma
- Phase II Breast cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer
- Phase I/II Glioma; Solid tumours
- Phase I Acute myeloid leukaemia
Most Recent Events
- 02 Dec 2018 Updated interim efficacy and adverse events data from a phase I trial in Acute myeloid leukaemia released by NewLink Genetics Corporation
- 01 Dec 2018 Updated adverse events data from a phase I trial in Acute myeloid leukaemia presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-2018)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Glioma(Combination therapy, In adolescents, In children, Second-line therapy or greater) in USA (PO, Capsule)